Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAPTIMMUNE THERAPEUTICS PLC

(ADAP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021

07/28/2021 | 08:12am EDT

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 28, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the second quarter ended June 30, 2021, after the US markets close on Monday, August 9, 2021. Following the announcement, the Company will host a live teleconference and webcast at 4:30 p.m. EDT (9:30 p.m. BST) that same day (details below).

The press release will be available in the investor section of Adaptimmune’s corporate website at www.adaptimmune.com. A live webcast of the conference call and replay can be accessed at https://bit.ly/3zFas59.

To participate in the live conference call, please dial (833) 652-5917 (U.S. or Canada) or +1 (430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (7867634).

About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 6, 2021, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts:

Media Relations:

Sébastien Desprez — VP, Communications and Investor Relations
T: +44 1235 430 583
M: +44 7718 453 176
Sebastien.Desprez@adaptimmune.com

Investor Relations:

Juli P. Miller, Ph.D. — Senior Director, Investor Relations
T: +1 215 825 9310
M: +1 215 460 8920
Juli.Miller@adaptimmune.com


Primary Logo


ę GlobeNewswire 2021
All news about ADAPTIMMUNE THERAPEUTICS PLC
09/22ADAPTIMMUNE THERAPEUTICS : Wells Fargo Adjusts Price Target on Adaptimmune Therapeutics to..
MT
09/21European ADRs Move Higher in Tuesday Trading
MT
09/16European ADRs Move Lower in Thursday Trading
MT
09/16ADAPTIMMUNE THERAPEUTICS : SURPASS ESMO poster September 16th, 2021th
PU
09/15European ADRs Modestly Higher Wednesday as Energy Stocks Rally
MT
09/14European ADRs Nudge Lower in Tuesday Trading
MT
09/13PRESENTATION DECK FOR BUILDING A CEL : SURPASS Phase 1 trial data at ESMO September 13, 20..
PU
09/13ADRs End Higher; Adaptimmune Therapeutics Among Companies Actively Trading
DJ
09/13ADAPTIMMUNE THERAPEUTICS : Cell Therapy Shows Antitumor Activity in Early Stage Study; Sha..
MT
09/13European ADRs Rise 1% Monday as Energy Giants Gain, Pharma Retreats
MT
More news
Analyst Recommendations on ADAPTIMMUNE THERAPEUTICS PLC
More recommendations
Financials (USD)
Sales 2021 5,45 M - -
Net income 2021 -125 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,07x
Yield 2021 -
Capitalization 899 M 899 M -
Capi. / Sales 2021 165x
Capi. / Sales 2022 63,3x
Nbr of Employees 462
Free-Float 7,21%
Chart ADAPTIMMUNE THERAPEUTICS PLC
Duration : Period :
Adaptimmune Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAPTIMMUNE THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 5,76 $
Average target price 8,80 $
Spread / Average Target 52,8%
EPS Revisions
Managers and Directors
Adrian Rawcliffe Chief Executive Officer & Director
Gavin Wood Chief Financial Officer
David M. Mott Chairman
Elliot Norry Chief Medical Officer
William C. Bertrand Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ADAPTIMMUNE THERAPEUTICS PLC6.86%899
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685
REGENERON PHARMACEUTICALS32.25%66 425
VERTEX PHARMACEUTICALS-22.31%47 634